Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
chronic toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
data from handbook or collection of data
Justification for type of information:
Data is from review article

Data source

Referenceopen allclose all

Reference Type:
review article or handbook
Title:
Repeated dose oral toxicity study of the test chemical
Author:
WHO
Year:
2016
Bibliographic source:
WHO Technical Report Series
Reference Type:
review article or handbook
Title:
Repeated dose oral toxicity study of the test chemical
Author:
European Commision
Year:
2004
Bibliographic source:
SCCNFP

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
other: Refer below principle
Principles of method if other than guideline:
Combined repeated dose carcinogenicity study using rats was performed to determine the toxic nature of the test chemical
GLP compliance:
not specified
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
1H-Indene-1,3(2H)-dione, 2-(2-quinolinyl)-, sulfonated, sodium salts
EC Number:
305-897-5
EC Name:
1H-Indene-1,3(2H)-dione, 2-(2-quinolinyl)-, sulfonated, sodium salts
Cas Number:
95193-83-2
Molecular formula:
C18H11NO5S to C18H8NO11S3.3Na
IUPAC Name:
trisodium hydrogen bis(2-(1,3-dioxo-5-sulfonato-2,3-dihydro-1H-inden-2-yl)quinoline-8-sulfonate)
Details on test material:
- Name of the test chemical: 1H-Indene-1,3(2H)-dione, 2-(2-quinolinyl)-, sulfonated, sodium salts
- Molecular formula: C18H9NNa2O8S2
- Substance type: Organic

Test animals

Species:
rat
Strain:
not specified
Sex:
male/female

Administration / exposure

Route of administration:
oral: feed
Vehicle:
other: Feed
Details on oral exposure:
PREPARATION OF DOSING SOLUTIONS: The test chemical was mixed with feed at dose levels of 0%, 0.03%, 0.1%, 0.5%, 2.0%, 5.0% (equivalent to 0, 15, 50, 250, 1000 or 2500 mg/kg bw per day, respectively)

DIET PREPARATION
- Rate of preparation of diet (frequency): No data
- Mixing appropriate amounts with (Type of food): No data
- Storage temperature of food: No data

VEHICLE
- Justification for use and choice of vehicle (if other than water): Feed
- Concentration in vehicle: 0%, 0.03%, 0.1%, 0.5%, 2.0%, 5.0% (equivalent to 0, 15, 50, 250, 1000 or 2500 mg/kg bw per day, respectively)
- Amount of vehicle (if gavage): Not appilcable
- Lot/batch no. (if required): No data
- Purity: No data
Analytical verification of doses or concentrations:
not specified
Details on analytical verification of doses or concentrations:
No data
Duration of treatment / exposure:
30 months (in utero phase)
Frequency of treatment:
Daily
Doses / concentrations
Remarks:
0%, 0.03%, 0.1%, 0.5%, 2.0%, 5.0% (equivalent to 0, 15, 50, 250, 1000 or 2500 mg/kg bw per day, respectively)
No. of animals per sex per dose:
70 males and 70 females
Control animals:
not specified
Details on study design:
No data
Positive control:
No data

Examinations

Observations and examinations performed and frequency:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Not specified
- Cage side observations checked in table [No.?] were included. Not specified

DETAILED CLINICAL OBSERVATIONS: Not specified
- Time schedule: Not specified

BODY WEIGHT: Yes
- Time schedule for examinations: Not specified

FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Not specified
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Not specified

FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Not specified

WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Not specified
- Time schedule for examinations: Not specified

OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Not specified
- Dose groups that were examined: Not specified

HAEMATOLOGY: Not specified
- Time schedule for collection of blood: Not specified
- Anaesthetic used for blood collection: Not specified
- Animals fasted: Not specified
- How many animals: Not specified
- Parameters checked in table [No.?] were examined. Not specified

CLINICAL CHEMISTRY: Not specified
- Time schedule for collection of blood: Not specified
- Animals fasted: Not specified
- How many animals: Not specified
- Parameters checked in table [No.?] were examined. Not specified

URINALYSIS: Not specified
- Time schedule for collection of urine: Not specified
- Metabolism cages used for collection of urine: Not specified
- Animals fasted: Not specified
- Parameters checked in table [No.?] were examined. Not specified

NEUROBEHAVIOURAL EXAMINATION: Not specified
- Time schedule for examinations: Not specified
- Dose groups that were examined: Not specified
- Battery of functions tested: sensory activity / grip strength / motor activity / other: Not specified

IMMUNOLOGY: Not specified
- Time schedule for examinations: Not specified
- How many animals: Not specified
- Dose groups that were examined: Not specified
- Parameters checked in table [No.?] were examined. Not specified

OTHER: Not specified
Sacrifice and pathology:
GROSS PATHOLOGY: Yes, absolute and relative organ weight was measured

HISTOPATHOLOGY: Yes, organs were observed for tissue damage and tumors (carcinogenic effects)
Other examinations:
No data
Statistics:
No data

Results and discussion

Results of examinations

Clinical signs:
no effects observed
Mortality:
not specified
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
Slight reductions in body weight were noted at at the two highest dose levels (2% and 5%)
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
no effects observed
Haematological findings:
not specified
Clinical biochemistry findings:
not specified
Urinalysis findings:
not specified
Behaviour (functional findings):
not specified
Immunological findings:
not specified
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Description (incidence and severity):
Changes in absolute and relative organ weights at the two highest dose levels (2% and 5%) were noted
Gross pathological findings:
not specified
Neuropathological findings:
not specified
Histopathological findings: non-neoplastic:
no effects observed
Histopathological findings: neoplastic:
no effects observed
Description (incidence and severity):
Carcinogenicity was not observed during the study
Other effects:
not specified

Effect levels

Dose descriptor:
NOAEL
Effect level:
250 mg/kg bw/day (actual dose received)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
body weight and weight gain
organ weights and organ / body weight ratios

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion

Conclusions:
The No observed adverse effect level (NOAEL) for the test chemical in a 30 months chronic-carcinogenicity study using male and female rats was considered to be 250 mg/Kg/day.
Executive summary:

Combined repeated dose-carcinogencity study was performed to determine the toxic nature of the test chemical. The study was performed for 30 months using 70 male and 70 female rats per dose group. The test chemical was mixed with feed at dose level of 0%, 0.03%, 0.1%, 0.5%, 2% or 5% (equivalent to 0, 15, 50, 250, 1000 or 2500 mg/kg bw per day, respectively). The animals were exposed to the test chemical in the in utero phase. The treated animals were observed for changes in clinical signs, body weight changes, opthalmology, organ weight changes, histopathology and carcinogenic effects. There were slight reductions in body weight and changes in absolute and relative organ weights at the two highest dose levels (2% and 5%). No other treatment related effects were noted. Based on the details of the study, the No observed adverse effect level (NOAEL) for the test chemical in a 30 months chronic-carcinogenicity study using male and female rats was noted to be 250 mg/Kg/day.